How have the shares performed?
Second Sight Medical Products Inc. (EYES) saw downtrend of -3.10% in the recent trading with $5.00 being its most recent. The current price level -75.00% lower than the highest price of $20.00 marked by the stock while trading over the past 52-weeks, whereas it is 624.01% higher than the lowest price of $0.69 the company dropped to over past 52-weeks. The latest news story on EYES appeared in Business Wire under the title “Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directors” on Apr-06-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -47.15% below one month high and is +7.99% above of the lowest during that time. Looking into the simple moving average, Second Sight Medical Products Inc. (EYES)’s stock stands at a SMA-50 of $8.52 while that of 5-day is reading $5.50.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and EYES’s SMA-200 as of now is $3.12.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock.
Second Sight Medical Products Inc. Earnings – What Happened With EYES
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Second Sight Medical Products Inc. (EYES) last released financial results for the quarter that ended 6/29/2020, posting a surprise factor of 63.40% for net revenue.
EYES – Second Sight Medical Products Inc. Stock Earnings Estimates
The perspective of Second Sight Medical Products Inc. (NASDAQ:EYES)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.41 for stock’s EPS in the current quarter. Company’s EPS for the last quarter was -0.15.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 23.16 million. EYES does have institutional investors; and they hold 2.50% of the stock.
Second Sight Medical Products Inc. – Insider Activity and Holdings
As on Dec 30, 2020, Vanguard Group, Inc. (The) was the top most holder in Second Sight Medical Products Inc. (NASDAQ:EYES) with an ownership of 0.41 million shares of the company or 1.45% of the stake worth $0.76 million. The filing also reveals Blackrock Inc. as the second largest holder in the company with a control over 1.35% of the outstanding shares. Its stake is worth $3.12 million for having 0.38 million shares in hand.
Geode Capital Management, LLC also came holding a key position in the company during the recent quarter and it now holds 0.26% of the outstanding shares. With this there are now 26 institutions which have possession in EYES’s shares.
Currently, the stock has been recommended as Moderate Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock.